 |
Recent News and Press Releases
June 16, 2008
Supratek Pharma appoints Dr. Alexander V. Kabanov to Board of Directors... more
March 31, 2008
Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SP1049C for the treatment of gastric cancer.... more
November 28, 2007
Supratek Pharma Inc. announced today that under the Special Protocol Assessment (SPA) process, it has obtained agreement with the United States Food and Drug Administration (FDA) for the design of its pivotal study protocol for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract... more
October 29, 2007
Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract... more
September 25, 2007
Supratek Pharma Inc. announced today the submission of an Investigational New Drug (IND) application and a request for Special Protocol Assessment (SPA) to the Division of Drug Oncology Products of U.S. Food and Drug Administration (FDA) for a new anticancer drug known as SP1049C... more
May 22, 2007
Supratek Pharma Inc. Files Preliminary Prospectus for Initial Public Offering of its Common Shares... more
June 3, 2006
Supratek announces positive results of its lead compound’s phase II trial at the American Society Clinical Oncology meeting in Atlanta... more
May 29, 2006
Supratek to present results of its lead compound’s phase II trial at the American Society Clinical Oncology meeting in Atlanta... more
|
